



PRESS RELEASE

ten23 health expands its sterile drug product manufacturing site at Visp, Switzerland

- The site, which was acquired last October from swissfillon, will expand into an adjacent building with an additional 1000 square meters of clean room space.
- The expansion will enlarge ten23 health's cold storage and visual inspection capacity and add clean rooms for additional services such as device assembly and secondary packaging by the end of 2022.

Basel, March 28, 2022. ten23 health®, a global contract development and manufacturing organization (CDMO) announced today a further expansion of swissfillon's manufacturing site in Visp, canton of Valais, Switzerland, which was acquired last October.

The FDA-inspected site in Visp currently offers sterile manufacturing of pre-filled syringes, vials, and cartridges for clinical trial and market supplies. To enable further growth of its existing production capacity, ten23 health is investing in an expansion of supporting areas in an adjacent building. This expansion will provide an additional 1000 square meters of clean-room space for visual inspection and cold storage and also include clean-room space for additional services, such as supporting device assembly operations and labeling and secondary packaging. The size of the investment is not disclosed.

Prof. Dr. Hanns-Christian Mahler, CEO of ten23 health, commented: *«Only five months ago, swissfillon joined ten23 health. This first expansion of the footprint in Visp is a strong commitment to our location in the Valais as well as Switzerland and a testimonial of the competent and experienced team at Visp. Furthermore, it is an important step in our long-term strategy to expand our manufacturing capacity for complex sterile dosage forms for our customers and their patients. »*

swissfillon, a leader in the sterile filling of complex pharmaceuticals, based in Visp, Switzerland was acquired by ten23 health in October 2021. ten23 health's combination of pharmaceutical development services with clinical and commercial fill & finish services offers clients an end-to-end set of capabilities. ten23 health launched its operations in Basel, Switzerland, in September 2021, with 4000 square meters of lab and office space, providing a work environment for up to 150 colleagues. Benefiting from the talented workforce in the Basel area, ten23 health has built up a team of accomplished leaders, scientists, and technicians over recent months.

About ten23 health®

ten23 health®, located in Basel, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients.

swissfillon, located in Visp, Switzerland, is a world leader in the sterile production of complex pharmaceutical dosage forms and a wholly-owned subsidiary of ten23 health. ten23 health combines the latest scientific findings with proven and tested world-class industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people's health and the future of our planet. ten23 health is solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner.

About the company's name

The numeric value for the number of molecules in a sample of one mol is called Avogadro constant and equals $6.022 \cdot 10^{23}$. The world is built from small units, and not a homogeneous mass.

About 3i Group

3i is an investment company with two complementary businesses, Private Equity, and Infrastructure, specializing in core investment markets in Northern Europe and North America. 3i's Private Equity team provides investment solutions for growing companies, backing entrepreneurs and management teams of mid-market companies with an Enterprise Value typically between €100m – €500m. The company backs international growth plans, providing access to its network and expertise to accelerate the growth of companies across the consumer, industrial, healthcare and business and technology services industries.

Media contacts:

ten23 health/swissfillon: Mara Willa, mara.willa@ten23.health; +41 27 948 31 70

3i Group: Kathryn van der Kroft, Kathryn.VanDerKroft@3i.com; +44 20 7975 3021